We attended the Pharma IPR event and had the chance to engage with leaders, innovators, and experts shaping the future of pharmaceutical IP.
What emerged was a striking reality: the rules of innovation are shifting. As drug discovery becomes faster, more data-driven, and increasingly AI-assisted, intellectual property is no longer just about protection, it is becoming the decisive factor in how value is created, defended, and scaled and questions around inventorship, licensing, and regulation are becoming central to how value is created.
The conversations reinforced a simple shift: innovation today needs to be built with IP in mind from the very beginning.
For us at Intelacia, it was a strong reminder of why forward-thinking IP strategy matters and why staying close to these conversations is key to helping our clients navigate what’s next.
